vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.1B, roughly 1.3× Elanco Animal Health Inc). Organon & Co. runs the higher net margin — -13.6% vs -24.1%, a 10.5% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs -5.3%). Organon & Co. produced more free cash flow last quarter ($96.0M vs $46.0M). Over the past eight quarters, Elanco Animal Health Inc's revenue compounded faster (-2.6% CAGR vs -3.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
ELAN vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.5B |
| Net Profit | $-276.0M | $-205.0M |
| Gross Margin | 51.5% | 49.2% |
| Operating Margin | -22.6% | -9.8% |
| Net Margin | -24.1% | -13.6% |
| Revenue YoY | 12.2% | -5.3% |
| Net Profit YoY | -3350.0% | -288.1% |
| EPS (diluted) | $-0.55 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $1.2B | $1.6B | ||
| Q1 25 | $1.2B | $1.5B | ||
| Q4 24 | $1.0B | $1.6B | ||
| Q3 24 | $1.0B | $1.6B | ||
| Q2 24 | $1.2B | $1.6B | ||
| Q1 24 | $1.2B | $1.6B |
| Q4 25 | $-276.0M | $-205.0M | ||
| Q3 25 | $-34.0M | $160.0M | ||
| Q2 25 | $11.0M | $145.0M | ||
| Q1 25 | $67.0M | $87.0M | ||
| Q4 24 | $-8.0M | $109.0M | ||
| Q3 24 | $364.0M | $359.0M | ||
| Q2 24 | $-50.0M | $195.0M | ||
| Q1 24 | $32.0M | $201.0M |
| Q4 25 | 51.5% | 49.2% | ||
| Q3 25 | 53.4% | 53.5% | ||
| Q2 25 | 57.5% | 54.8% | ||
| Q1 25 | 57.3% | 55.6% | ||
| Q4 24 | 50.9% | 56.3% | ||
| Q3 24 | 52.2% | 58.3% | ||
| Q2 24 | 58.2% | 58.4% | ||
| Q1 24 | 57.3% | 59.0% |
| Q4 25 | -22.6% | -9.8% | ||
| Q3 25 | -4.4% | 15.2% | ||
| Q2 25 | 2.0% | 14.4% | ||
| Q1 25 | 5.0% | 6.7% | ||
| Q4 24 | -5.0% | 8.1% | ||
| Q3 24 | 54.3% | 13.1% | ||
| Q2 24 | -2.7% | 14.6% | ||
| Q1 24 | 1.0% | 14.5% |
| Q4 25 | -24.1% | -13.6% | ||
| Q3 25 | -3.0% | 10.0% | ||
| Q2 25 | 0.9% | 9.1% | ||
| Q1 25 | 5.6% | 5.8% | ||
| Q4 24 | -0.8% | 6.8% | ||
| Q3 24 | 35.3% | 22.7% | ||
| Q2 24 | -4.2% | 12.1% | ||
| Q1 24 | 2.7% | 12.4% |
| Q4 25 | $-0.55 | $-0.78 | ||
| Q3 25 | $-0.07 | $0.61 | ||
| Q2 25 | $0.02 | $0.56 | ||
| Q1 25 | $0.13 | $0.33 | ||
| Q4 24 | $-0.01 | $0.42 | ||
| Q3 24 | $0.73 | $1.38 | ||
| Q2 24 | $-0.10 | $0.75 | ||
| Q1 24 | $0.06 | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $574.0M |
| Total DebtLower is stronger | $3.9B | $8.6B |
| Stockholders' EquityBook value | $6.5B | $752.0M |
| Total Assets | $13.4B | $12.9B |
| Debt / EquityLower = less leverage | 0.60× | 11.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $574.0M | ||
| Q3 25 | $505.0M | $672.0M | ||
| Q2 25 | $539.0M | $599.0M | ||
| Q1 25 | $487.0M | $547.0M | ||
| Q4 24 | $468.0M | $675.0M | ||
| Q3 24 | $490.0M | $763.0M | ||
| Q2 24 | $416.0M | $704.0M | ||
| Q1 24 | $345.0M | $575.0M |
| Q4 25 | $3.9B | $8.6B | ||
| Q3 25 | $4.0B | $8.8B | ||
| Q2 25 | $4.1B | $8.9B | ||
| Q1 25 | $4.4B | $9.0B | ||
| Q4 24 | $4.3B | $8.9B | ||
| Q3 24 | $4.4B | $8.7B | ||
| Q2 24 | $5.7B | $8.7B | ||
| Q1 24 | $5.8B | $8.7B |
| Q4 25 | $6.5B | $752.0M | ||
| Q3 25 | $6.7B | $906.0M | ||
| Q2 25 | $6.8B | $733.0M | ||
| Q1 25 | $6.4B | $542.0M | ||
| Q4 24 | $6.1B | $472.0M | ||
| Q3 24 | $6.5B | $493.0M | ||
| Q2 24 | $5.9B | $144.0M | ||
| Q1 24 | $6.1B | $48.0M |
| Q4 25 | $13.4B | $12.9B | ||
| Q3 25 | $13.6B | $13.6B | ||
| Q2 25 | $13.7B | $13.5B | ||
| Q1 25 | $12.9B | $13.2B | ||
| Q4 24 | $12.6B | $13.1B | ||
| Q3 24 | $13.3B | $12.8B | ||
| Q2 24 | $13.8B | $12.2B | ||
| Q1 24 | $14.0B | $11.9B |
| Q4 25 | 0.60× | 11.49× | ||
| Q3 25 | 0.59× | 9.74× | ||
| Q2 25 | 0.61× | 12.14× | ||
| Q1 25 | 0.69× | 16.52× | ||
| Q4 24 | 0.70× | 18.81× | ||
| Q3 24 | 0.67× | 17.75× | ||
| Q2 24 | 0.96× | 60.11× | ||
| Q1 24 | 0.95× | 181.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $141.0M |
| Free Cash FlowOCF − Capex | $46.0M | $96.0M |
| FCF MarginFCF / Revenue | 4.0% | 6.4% |
| Capex IntensityCapex / Revenue | 5.4% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $538.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $141.0M | ||
| Q3 25 | $219.0M | $264.0M | ||
| Q2 25 | $237.0M | $220.0M | ||
| Q1 25 | $-4.0M | $75.0M | ||
| Q4 24 | $177.0M | $390.0M | ||
| Q3 24 | $162.0M | $141.0M | ||
| Q2 24 | $200.0M | $332.0M | ||
| Q1 24 | $2.0M | $76.0M |
| Q4 25 | $46.0M | $96.0M | ||
| Q3 25 | $127.0M | $218.0M | ||
| Q2 25 | $180.0M | $181.0M | ||
| Q1 25 | $-69.0M | $43.0M | ||
| Q4 24 | $130.0M | $335.0M | ||
| Q3 24 | $120.0M | $99.0M | ||
| Q2 24 | $166.0M | $300.0M | ||
| Q1 24 | $-22.0M | $30.0M |
| Q4 25 | 4.0% | 6.4% | ||
| Q3 25 | 11.2% | 13.6% | ||
| Q2 25 | 14.5% | 11.4% | ||
| Q1 25 | -5.8% | 2.8% | ||
| Q4 24 | 12.7% | 21.0% | ||
| Q3 24 | 11.7% | 6.3% | ||
| Q2 24 | 14.0% | 18.7% | ||
| Q1 24 | -1.8% | 1.8% |
| Q4 25 | 5.4% | 3.0% | ||
| Q3 25 | 8.1% | 2.9% | ||
| Q2 25 | 4.6% | 2.4% | ||
| Q1 25 | 5.4% | 2.1% | ||
| Q4 24 | 4.6% | 3.5% | ||
| Q3 24 | 4.1% | 2.7% | ||
| Q2 24 | 2.9% | 2.0% | ||
| Q1 24 | 2.0% | 2.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | 21.55× | 1.52× | ||
| Q1 25 | -0.06× | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | 0.45× | 0.39× | ||
| Q2 24 | — | 1.70× | ||
| Q1 24 | 0.06× | 0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
OGN
Segment breakdown not available.
